You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,622,854


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,622,854
Title: Method and reagent for inhibiting T-cell leukemia virus replication
Abstract:An enzymatic RNA molecule which specifically cleaves RNA of HTLV-1.
Inventor(s): Draper; Kenneth G. (Solon, OH)
Assignee: Ribozyme Pharmaceuticals Inc. (Boulder, CO)
Application Number:08/192,941
Patent Claims:1. An enzymatic RNA molecule which specifically cleaves RNA of HTLV-1.

2. The enzymatic RNA molecule of claim 1 which cleaves RNA in the tax, rex, and pro gene regions.

3. The enzymatic RNA molecule of claim 1 which cleaves RNA in the 5'-LTR and 3'-LTR regions.

4. The enzymatic RNA molecule of claim 1 wherein said RNA molecule is in a hammerhead motif.

5. The enzymatic RNA molecule of claim 1 wherein said RNA molecule is in a hairpin, hepatitis Delta virus, group 1 intron, or RNaseP RNA motif.

6. The enzymatic RNA molecule of claim 1 which specifically cleaves a sequence comprising any of SEQ. ID. NOS. 1-25, wherein said enzymatic RNA molecule is in a hammerhead or hepatitis Delta virus motif.

7. The enzymatic RNA of any of claims 1, 2-6 wherein said ribozyme comprises between 5 and 23 bases complementary to the RNA of said gene or region.

8. The enzymatic RNA of any of claim 7 wherein said ribozyme comprises between 10 and 18 bases complementary to the RNA of said gene or region.

9. A mammalian cell including an enzymatic RNA molecule of any of claims 1, 2-6 in vitro.

10. The cell of claim 9, wherein said cell is a human cell.

11. An expression vector including a nucleic acid encoding the enzymatic RNA molecule of any of claims 1, 2-6, in a manner which allows expression of that enzymatic RNA molecule within a mammalian cell, in vitro.

Details for Patent 5,622,854

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2014-04-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2014-04-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2014-04-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.